Fig. 5From: Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotateAbsorbed doses in Gy in liver, kidneys, spleen, and red marrow after cycle 1 and after cycle 2. As our dosimetry methodology was based on L2-L3-L4 red marrow delineation, it could not be used for patients 3 and 11 who had tumors in contact with L2, L3, L4 and L2, L3 or L4 vertebral metastasesBack to article page